Myrte K Neijenhuis1, Tom J G Gevers1, Marie C Hogan2, Patrick S Kamath3, Titus F M Wijnands1, Ralf C P M van den Ouweland1, Marie E Edwards2, Jeff A Sloan4, Wietske Kievit5, Joost P H Drenth1. 1. Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 2. Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 4. Quality of Life Group, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 5. Radboud Institute for Health Sciences, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Abstract
UNLABELLED: Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease-specific questionnaire that assesses symptoms in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by literature review and interviews with patients and clinicians. The developed PLD-Q was validated in Dutch (n = 200) and United States (US; n = 203) PLD patients. We assessed the correlation of PLD-Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume. To test discriminative validity, we compared PLD-Q total scores of patients with different PLD severity stages (Gigot classification) and PLD-Q total scores of PLD patients with general controls and polycystic kidney disease patients without PLD. Reproducibility was tested by comparing original test scores with 2-week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = -0.517; US, r = -0.593) was good. There was no correlation of PLD-Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type II patients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLD patients scored higher on the PLD-Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney disease patients without PLD (22 points). Reproducibility of PLD-Q was excellent (NL, r = 0.94; US, 0.96). CONCLUSION: PLD-Q is a valid, reproducible, and sensitive disease-specific questionnaire that can be used to assess PLD-related symptoms in clinical care and future research. (Hepatology 2016;64:151-160).
UNLABELLED: Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease-specific questionnaire that assesses symptoms in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by literature review and interviews with patients and clinicians. The developed PLD-Q was validated in Dutch (n = 200) and United States (US; n = 203) PLDpatients. We assessed the correlation of PLD-Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume. To test discriminative validity, we compared PLD-Q total scores of patients with different PLD severity stages (Gigot classification) and PLD-Q total scores of PLDpatients with general controls and polycystic kidney diseasepatients without PLD. Reproducibility was tested by comparing original test scores with 2-week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = -0.517; US, r = -0.593) was good. There was no correlation of PLD-Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type IIpatients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLDpatients scored higher on the PLD-Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney diseasepatients without PLD (22 points). Reproducibility of PLD-Q was excellent (NL, r = 0.94; US, 0.96). CONCLUSION:PLD-Q is a valid, reproducible, and sensitive disease-specific questionnaire that can be used to assess PLD-related symptoms in clinical care and future research. (Hepatology 2016;64:151-160).
Authors: Joshua D Warner; Maria V Irazabal; Ganapathy Krishnamurthi; Bernard F King; Vicente E Torres; Bradley J Erickson Journal: J Digit Imaging Date: 2014-08 Impact factor: 4.056
Authors: Titus F M Wijnands; Myrte K Neijenhuis; Wietske Kievit; Frederik Nevens; Marie C Hogan; Vicente E Torres; Tom J G Gevers; Joost P H Drenth Journal: Liver Int Date: 2014-01-09 Impact factor: 5.828
Authors: Loes Van Keimpema; Daan B De Koning; Bart Van Hoek; Aad P Van Den Berg; Martijn G H Van Oijen; Robert A De Man; Frederik Nevens; Joost P H Drenth Journal: Liver Int Date: 2011-01 Impact factor: 5.828
Authors: Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth Journal: Gastroenterology Date: 2009-07-29 Impact factor: 22.682
Authors: James G Orr; Tara Homer; Laura Ternent; Julia Newton; Calum J McNeil; Mark Hudson; David E J Jones Journal: J Hepatol Date: 2014-07-07 Impact factor: 25.083
Authors: Lucas H P Bernts; Myrte K Neijenhuis; Marie E Edwards; Jeff A Sloan; Jenna Fischer; Rory L Smoot; David M Nagorney; Joost P H Drenth; Marie C Hogan Journal: Surgery Date: 2020-05-08 Impact factor: 3.982
Authors: Myrte Neijenhuis; Tom J G Gevers; Thomas D Atwell; Tim J Gunneson; Amanda C Schimek; Wietske Kievit; Joost P H Drenth; Patrick S Kamath Journal: Am J Gastroenterol Date: 2018-03-20 Impact factor: 10.864
Authors: Neil Rajoriya; Dhiraj Tripathi; Joanna A Leithead; Bridget K Gunson; Sophie Lord; James W Ferguson; Gideon M Hirschfield Journal: World J Gastroenterol Date: 2016-12-07 Impact factor: 5.742
Authors: Titus F M Wijnands; Tom J G Gevers; Marten A Lantinga; René H Te Morsche; Leo J Schultze Kool; Joost P H Drenth Journal: Eur Radiol Date: 2018-01-09 Impact factor: 5.315
Authors: Myrte K Neijenhuis; Titus F M Wijnands; Wietske Kievit; Maxime Ronot; Tom J G Gevers; Joost P H Drenth Journal: Eur Radiol Date: 2018-12-12 Impact factor: 5.315
Authors: Marie C Hogan; Julie A Chamberlin; Lisa E Vaughan; Angela L Waits; Carly Banks; Kathleen Leistikow; Troy Oftsie; Chuck Madsen; Marie Edwards; James Glockner; Walter K Kremers; Peter C Harris; Nicholas F LaRusso; Vicente E Torres; Tatyana V Masyuk Journal: Clin J Am Soc Nephrol Date: 2020-08-25 Impact factor: 8.237
Authors: Titus Fm Wijnands; Bastian Schoenemeier; Andrej Potthoff; Tom Jg Gevers; Hans Groenewoud; Michael J Gebel; Kinan Rifai; Michael P Manns; Joost Ph Drenth Journal: United European Gastroenterol J Date: 2018-03-08 Impact factor: 4.623